NeoTract Study Finds That Men Over 40 Are Not
Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH)
Can Cause Permanent Bladder Damage or of Treatment Options
NeoTract, a wholly owned subsidiary of Teleflex Incorporated
(NYSE:TFX) focused on addressing unmet needs in the field of
urology, today announced new data showing that both men and women
have many misconceptions about benign prostatic hyperplasia (BPH)
treatment options and side effects, as well as the impact of the
condition on men’s overall health – suggesting that a focus on
better understanding of this common condition may be in order for
the new year.
BPH, also known as enlarged prostate, is non-cancerous
enlargement of the prostate that occurs as men age. The condition
affects over 40 million men in the United States alone, with more
than 40 percent of men over 50 and 80 percent of men over 70 having
BPH. The symptoms of BPH can cause loss of productivity, depression
and decreased quality of life. In addition, if left untreated the
condition can worsen over time and cause permanent bladder
damage.1
“Data clearly show that both men and women have significant
misconceptions about men’s health, including BPH and the ways to
treat the condition,” said Ana Fadich, vice president of Men’s
Health Network. “If men are experiencing any of the symptoms
associated with enlarged prostate, we encourage them to use the New
Year as an opportunity to be proactive about their health by
talking with their doctor. As men age, early intervention can make
a huge difference in their long-term quality of life.”
Two recent surveys sponsored by NeoTract were conducted among
1,000 men and 1,000 women over the age of 40 in the United States,
with the goal of understanding participants’ beliefs about BPH
versus what is factual about the condition. The results
demonstrated that many of the surveyed men and women are not aware
of BPH treatment options beyond medication. The survey also found
that half of the men who have been diagnosed with BPH reported that
their doctors informed them of medication as a treatment for their
BPH, while only eight percent said their doctors spoke with them
about minimally invasive/outpatient treatments as an option.
“Medication is often the first-line therapy for enlarged
prostate, but relief can be inadequate and temporary. Patients can
experience headaches or dizziness when taking BPH medication, as
well as other negative side effects such as sexual dysfunction,
often causing them to quit taking BPH medication altogether,” said
Gregg R. Eure*, M.D., F.A.C.S., of Urology of
Virginia and Eastern Virginia Medical School. “Fortunately, there
are alternative treatments to medication for men with BPH including
NeoTract’s UroLift® System, a minimally invasive treatment that is
clinically proven to be one of the only BPH treatment options to
rapidly and effectively treat urinary symptoms while preserving
sexual function. **1-3 It can break the cycle of side effects
caused by medications, enhancing a man’s quality of life without
the risk of more invasive surgery.”
Many men and women were not aware that minimally invasive
procedures are available to treat BPH. Of the participants
surveyed:
- 50 percent were aware that medications
are available to treat their BPH, but only six percent were aware
that minimally invasive procedures like the UroLift System
procedure or PUL are available as treatment options.
- More than 75% of male respondents said
that their doctor had not spoken to them about a minimally invasive
procedure as an alternative to BPH medication.
- 49% of men surveyed who have BPH are
using medication to treat their condition. 48% of these individuals
are interested in a solution to get off their BPH medication.
- Over 90 percent said that they were
“very likely” or “somewhat likely” to seek minimally invasive
procedures if they carried less risk of impotence or
incontinence.
Unfortunately, men sometimes avoid talking with their doctor
about symptoms because of the perceived side effects of BPH
treatment options. Men and women surveyed highlighted their fears
with treating BPH:
- 30 percent of men reported that they
are not treating their BPH because the treatment options available
are not appealing to them, in other words, they “don’t want to take
medication or have surgery”.
- 31 percent of male respondents and 25
percent of female respondents with male partners believe BPH
treatment options can cause impotence or risk of incontinence.
Both men and women also have misconceptions about BPH as a
pre-cursor to prostate cancer. Although there is no known link
between BPH and later prostate cancer,4 41 percent of men and 55
percent of women surveyed believe that men who have BPH are at a
high risk for prostate cancer. In actuality, BPH is a benign
condition and unrelated to prostate cancer; however, it can greatly
affect a man’s quality of life.
“These study results show that there is still much to be done to
educate both men and women about BPH and its treatment options.
This is not surprising, as we know that men tend to ignore the
symptoms associated with BPH and believe it’s an inevitable part of
aging,” said Dave Amerson, president of NeoTract | Teleflex
Interventional Urology. “We are excited that, when informed of the
facts and their options, so many men are choosing the UroLift
System as a treatment for BPH.”
About the UroLift® System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants,
delivered during a minimally invasive transurethral outpatient
procedure, relieve prostate obstruction and open the urethra
directly without cutting, heating, or removing prostate tissue.
Clinical data from a pivotal 206-patient randomized controlled
study showed that patients with enlarged prostate receiving UroLift
implants reported rapid and durable symptomatic and urinary flow
rate improvement without compromising sexual function. Patients
also experienced a significant improvement in quality of life. Over
80,000 men have been treated with the UroLift System in the U.S.
Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most
symptoms were mild to moderate in severity and resolved within two
to four weeks after the procedure. The UroLift System Prostatic
Urethral Lift procedure is recommended for the treatment of BPH in
both the American Urological Association and European Association
of Urology clinical guidelines. The UroLift System is available in
the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn
more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the
Interventional Urology Business Unit is dedicated to developing
innovative, minimally invasive and clinically effective devices
that address unmet needs in the field of urology. Our initial focus
is on improving the standard of care for patients with BPH using
the UroLift System, a minimally invasive permanent implant system
that treats symptoms while preserving normal sexual function. Learn
more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose.
*Dr. Eure is a paid consultant of NeoTract | Teleflex and is
part of the NeoTract faculty.
**No instances of new, sustained erectile or ejaculatory
dysfunction
- Tubaro et al. 2003 Drugs Aging
- McVary, J Sex Med 2014
- Roehrborn, J Urology 2013 LIFT
Study
- Chang, The Practitioner 2012
MAC00927-01 Rev B
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190116005072/en/
For Teleflex Incorporated:Jake Elguicze, 610.948.2836Treasurer
and Vice President, Investor Relations
Media:Nicole Osmer, 650.454.0504nicole@healthandcommerce.com
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024